75717-77-0 Usage
General Description
2,4-dichloro-1-ethynylbenzene is a chemical compound that belongs to the family of benzene derivatives. It is also known by the systematic name 1-ethynyl-2,4-dichlorobenzene. 2,4-dichloro-1-ethynylbenzene is a colorless liquid with a slightly sweet odor, and it is insoluble in water. It is primarily used as an intermediate in the production of other organic compounds, including pesticides and pharmaceuticals. Additionally, it is also used in the synthesis of other chemicals, such as dyes and plasticizers. However, it is important to handle this compound with care, as it can be harmful if it comes into contact with the skin or if it is inhaled.
Check Digit Verification of cas no
The CAS Registry Mumber 75717-77-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,7,1 and 7 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 75717-77:
(7*7)+(6*5)+(5*7)+(4*1)+(3*7)+(2*7)+(1*7)=160
160 % 10 = 0
So 75717-77-0 is a valid CAS Registry Number.
75717-77-0Relevant articles and documents
1,2,3-triazole compounds with antitumor activity and preparation method for 1,2,3-triazole compounds
-
Paragraph 0060; 0061, (2016/10/10)
The present invention relates to three 1,2,3-triazole compounds with aryl structures on the left sides, and the general structural formulae thereof are as shown in the specification. The three compounds have good antitumor activity.
Convenient synthesis of terminal alkynes from anti-3-aryl-2,3- dibromopropanoic acids using a K2CO3/DMSO system
Cheng, Xuezhi,Jia, Jun,Kuang, Chunxiang
, p. 2350 - 2354 (2012/02/03)
A convenient, efficient, and generally applicable method was developed for the synthesis of terminal alkynes from anti-3-aryl-2,3-dibromopropanoic acids in the presence of DMSO and K2CO3.
CRF receptor antagonists and methods relating thereto
-
Page column 15, (2008/06/13)
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.